The companies have partnered with the goal of streamlining point-of-care access to Guardant's genomic cancer test portfolio.

The UK government said that it plans this year to repeal regulations specific to COVID-19 tests as part of the alignment with EU Common Specifications.

The acquisition was opposed by some Quanterix shareholders. In May, Akoya also said it received an unsolicited acquisition bid for the firm.